Legal Representation
Attorney
Jeffrey H. Handelsman
USPTO Deadlines
Next Deadline
396 days remaining
Section 71 Renewal Due (Principal Register 66a) (Based on registration date 20170124)
Due Date
January 24, 2027
Grace Period Ends
July 24, 2027
Application History
49 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 9, 2025 | RNWL | P | INTERNATIONAL REGISTRATION RENEWED | Loading... |
| Apr 18, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 12, 2023 | INNP | P | PARTIAL INVALIDATION PROCESSED BY THE IB | Loading... |
| Oct 11, 2023 | INPS | P | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | Loading... |
| Oct 11, 2023 | INPC | P | INVALIDATION PROCESSED | Loading... |
| Oct 6, 2023 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Feb 6, 2023 | NA71 | E | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | Loading... |
| Feb 6, 2023 | 71AG | O | REGISTERED-SEC.71 ACCEPTED | Loading... |
| Feb 3, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Jan 29, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Jan 19, 2023 | ES71 | I | TEAS SECTION 71 RECEIVED | Loading... |
| Jan 24, 2022 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| Aug 4, 2017 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| May 12, 2017 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Apr 25, 2017 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Apr 25, 2017 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Apr 24, 2017 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jan 24, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jan 6, 2017 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Jan 4, 2017 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jan 4, 2017 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Nov 8, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 8, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 19, 2016 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Oct 19, 2016 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Oct 19, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 3, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Sep 24, 2016 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 20, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 19, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 19, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 17, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 17, 2016 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 17, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 25, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 25, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 19, 2016 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 15, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 15, 2016 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 15, 2016 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Sep 4, 2015 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 14, 2015 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 14, 2015 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Aug 14, 2015 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Aug 13, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 11, 2015 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Aug 8, 2015 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 6, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 30, 2015 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Monoclonal antibodies for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; [ biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; ] medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders [ ; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; dietary supplements for humans; nutritional supplements; dietary supplements for animals; dietetic foods, namely, protein adapted for medical purposes; dietetic beverages, namely, protein-based ready to drink beverages adapted for medical purposes; food for babies; powdered milk for babies; lacteal flour for babies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]
Class 042
Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; research and development in the field of biotechnology; ] pharmaceutical research and development [ ; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ]
Additional Information
Design Mark
The mark consists of a stylized "X" in white, within a blue square. Centered below the "X" is the term "CHIOME" in blue.
Color Claim
The color(s) blue and white is/are claimed as a feature of the mark.
Classification
International Classes
005
042